Start here: borrowing a volume expander
Many people with POTS have a reduced blood volume, which makes standing harder because there is less blood to circulate against gravity. Fludrocortisone, a mineralocorticoid steroid, tackles that directly by prompting the kidneys to retain salt and water, expanding the volume.
That is the logic for using it in long COVID POTS. It is not a long-COVID drug; it is borrowed from the treatment of orthostatic disorders and applied off-label. No treatment is approved for long COVID, so fludrocortisone here is a reasonable, evidence-informed borrowing rather than a proven cure.
targets the low blood volume of POTSdirect trial evidence limitedoff-label; no long-COVID-specific approval
How it is meant to work
By signalling the kidneys to hold sodium and water, fludrocortisone raises the circulating blood volume and can blunt the drop in blood return to the heart on standing. With more volume in the system, heart rate does not need to spike as much to maintain circulation.
It is usually combined with the non-drug basics: increased fluid and salt intake and compression garments. The drug essentially reinforces those measures chemically, which is why it is often tried when fluids, salt, and compression alone are not enough. Because it works by expanding volume rather than slowing the heart directly, it is sometimes paired with a heart-rate-lowering drug so the two address different parts of the problem at once.
What the evidence shows
The honest picture is modest. A systematic review of POTS after COVID found that non-drug measures were often insufficient and that medications including fludrocortisone, beta-blockers, and midodrine were used with symptoms tending to improve, but the data were limited and largely uncontrolled.
The dedicated evidence for fludrocortisone itself comes mostly from orthostatic hypotension, a related but different condition, where a Cochrane review found only very low-certainty evidence from small, short trials. So its use in POTS rests on physiological logic and clinical experience more than strong trials.
evidence extrapolated from orthostatic hypotension
Practical considerations
Fludrocortisone requires monitoring. Because it makes the body retain salt and water, it can lower potassium and raise blood pressure, so clinicians typically check potassium and watch for swelling or headaches. It is not suitable for everyone, particularly those with high blood pressure or heart failure. It can also take a couple of weeks to show its full effect, so it is not judged on the first few days but over a longer trial period.
Dosing is individual and usually started low. The point is that this is a real medication with real trade-offs, prescribed and monitored by a clinician, not a supplement to self-start. Its place is as one option within a broader POTS management plan.
What it means for you
If you have POTS-type symptoms after COVID and the basics are not enough, fludrocortisone is a legitimate option to discuss with a clinician, with realistic expectations: it helps some people partially, it is not a cure, and it needs monitoring.
It works best as part of a package that includes fluids, salt, compression, and paced activity, rather than as a standalone fix. Matching the treatment to your specific pattern, with medical guidance, matters more than any single drug.
How to read claims about it
Be wary of sources presenting fludrocortisone, or any single POTS drug, as a reliable cure for long COVID. The evidence supports modest, partial benefit for some, not a fix, and the strongest data come from a different condition.
The honest stance is that it is a reasonable, monitored option worth trying when indicated, and not a guaranteed answer. Judge it by whether your symptoms actually improve on it, with a clinician tracking the trade-offs, rather than by marketing or anecdote.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- How well fludrocortisone works specifically for post-COVID POTS in controlled trials.
- Which patients are most likely to benefit.
- How it compares with other POTS drugs head to head.
- The best dosing and duration for long COVID POTS.
- How much of any benefit is the drug versus the accompanying fluid and salt measures.
- Long-term safety in this younger, predominantly female population.
What this means for you
Fludrocortisone targets the low blood volume behind many POTS symptoms and is a legitimate off-label option when fluids, salt, and compression are not enough. It helps some people partially and needs clinician monitoring of potassium and blood pressure.
The trial evidence is limited and borrowed largely from orthostatic hypotension, and no treatment is approved for long COVID, so judge it by whether your symptoms improve rather than treating it as a cure.
References
Each reference links to the source on PubMed, PMC, or the publisher.